Baseline characteristics of the study participants
| Characteristic | Placebo (n=258) | Anti-Hp+ celecoxib (n=255) | Anti-Hp+placebo (n=255) | Celecoxib+placebo (n=256) | p Value |
| Age (years) | 52.9±6.5 | 53.0±6.5 | 53.0±6.5 | 52.9±6.5 | 0.999 |
| Sex | 0.998 | ||||
| Men | 120 (46.5) | 118 (46.3) | 118 (46.3) | 117 (45.7) | |
| Women | 138 (53.5) | 137 (53.7) | 137 (53.7) | 139 (54.3) | |
| Daily smoking | 0.944 | ||||
| Yes | 166 (68.6) | 168 (70.9) | 169 (70.7) | 168 (69.7) | |
| No | 76 (31.4) | 69 (29.1) | 70 (29.3) | 73 (30.3) | |
| Alcohol use | 0.581 | ||||
| Yes | 148 (61.2) | 156 (65.8) | 158 (66.1) | 150 (62.2) | |
| No | 94 (38.8) | 81 (34.2) | 81 (33.9) | 91 (37.3) | |
| Baseline histology | 0.287 | ||||
| CAG | 65 (25.2) | 53 (20.8) | 59 (23.1) | 50 (19.5) | |
| IM | 63 (24.4) | 64 (25.1) | 59 (23.1) | 54 (21.1) | |
| Ind DYS | 113 (43.8) | 108 (42.4) | 115 (45.1) | 133 (52.0) | |
| DYS | 17 (6.6) | 30 (11.7) | 22 (8.7) | 19 (7.4) |
Anti-Hp, anti-H pylori treatment; CAG, chronic atrophic gastritis; DYS, dysplasia; IM, intestinal metaplasia; Ind DYS, indefinite dysplasia.